Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab's (ZLAB) experimental drug Zoci showed an 82% response rate in an early lung cancer study. The 1.6 mg/kg cohort had 81.9% six-month progression-free survival. Zoci with atezolizumab and carboplatin had a 92.3% response rate but increased toxicity. Zai Lab plans a global Phase III study by 2026, aiming to replace chemotherapy in frontline treatment. The company expects multiple program readouts and a potential U.S. biologics license application submission next year.

Zai Lab (ZLAB) stock rose 7.2% to $23.62 after releasing Phase 1b trial data for its oncology drug zocilurtatug pelitecan, showing an 81.8% response rate. The company also announced a $250M capital raise from institutional investors. Analysts have an average price target above current levels.

Zai Lab reported that zoci 1.6 mg/kg plus atezolizumab showed an 81.8% ORR and 81.9% 6-month PFS rate in first-line ES-SCLC. Grade >3 AEs related to zoci were 9.1%. A Phase 3 study is planned to start by year-end 2026, according to the company.

Zai Lab's (ZLAB) drug zocilurtatug pelitecan (zoci) showed 81.8% response rate and 81.9% 6-month progression-free survival in a Phase 1b trial for extensive-stage small cell lung cancer. The combination with atezolizumab was well-tolerated. A Phase 3 trial is planned for 2026. Zai Lab will discuss the data in an investor call.

Zai Lab (ZLAB, 9688) reported Phase 1b trial data for zocilurtatug pelitecan with atezolizumab in lung cancer treatment. At 1.6 mg/kg, 81.8% response rate and 81.9% six-month progression-free survival were observed. Adverse events were mostly mild. A triplet regimen showed 92.3% response rate but higher severe adverse events. Zai Lab plans a Phase 3 study by year-end 2026.

Zai Lab reported Phase 1b data for zocilurtatug pelitecan in first-line ES-SCLC, showing high response rates and tolerability. The company plans to start a global Phase 3 study. According to the company, the data supports a platinum-free regimen with atezolizumab.